Do your simvastatin patients need more help reaching their LDL-C goals?

LIPITOR® (atorvastatin calcium) tablets provide LDL-C reductions of 39% to 60% across the full dose range1

LIPITOR® (atorvastatin calcium) tablets are contraindicated in patients with a known hypersensitivity to any component of this product; in patients with active liver disease or unexplained persistent elevations of hepatic transaminases; in women who are or may become pregnant or who are nursing.

Lipitor. Proven to help lower LDL-C, backed by 20 years of experience1
 

As seen in CURVES, LIPITOR showed significantly greater LDL-C reductions than simvastatin across a range of doses.2

The FDA recommends that patients who do not meet their LDL-C goal on simvastatin 40 mg be placed on alternative LDL-C-lowering treatments.3

Study Background

CURVES (N=534) was an 8-week, randomized, open-label, parallel-group study that compared milligram-equivalent doses of LIPITOR® (atorvastatin calcium) tablets with simvastatin, pravastatin, lovastatin, and fluvastatin in patients with LDL-C ≥160 mg/dL and TG ≤400 mg/dL. Baseline LDL-C values were similar and patient demographics evenly distributed across treatment groups. Patients were randomized to LIPITOR 10 mg (n=73), 20 mg (n=51), 40 mg (n=61), or 80 mg (n=10); simvastatin 10 mg (n=70), 20 mg (n=49), or 40 mg (n=61); pravastatin 10 mg (n=14), 20 mg (n=41), or 40 mg (n=25); or lovastatin 20 mg (n=16), 40 mg (n=16), or 80 mg (n=11).

LIPITOR 10 mg, 20 mg, and 40 mg produced greater reductions in LDL-C (38%, 46%, and 51%, respectively; P≤.01) compared with equivalent doses of simvastatin, pravastatin, lovastatin, and fluvastatin. LIPITOR 10 mg produced LDL-C reductions comparable with or greater than simvastatin 10 mg, 20 mg, and 40 mg (28%, 35%, and 41%, respectively); pravastatin 10 mg, 20 mg, and 40 mg (19%, 24%, and 34%, respectively); lovastatin 20 mg and 40 mg (29% and 31%, respectively); and fluvastatin 20 mg and 40 mg (17% and 23%, respectively).2

References

  1. LIPITOR Product Document [all data referenced to the LPD have to be: a) reviewed and adapted according to the country-specific regulation; b) referenced with and in accordance to the local LIPITOR prescribing information].
  2. Jones P, Kafonek S, Laurora I, Hunninghake D; for CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-587.
  3. US Food and Drug Administration website. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm. Updated February 2, 2012. Accessed October 26, 2015.